Insmed Statistics
Insmed (IM8N) Stock Statistics & Valuation Metrics
Total Valuation
Insmed has a market cap or net worth of CHF 21.72B. The enterprise value is CHF 24.58B.
- Market Cap
- CHF 21.72B
- Enterprise Value
- CHF 24.58B
Share Statistics
Insmed has 219,380,310 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 219,380,310
- Owned by Insiders
- 0.70%
- Owned by Institutions
- 71.04%
Financial Efficiency
Insmed’s return on equity (ROE) is -1.73 and return on invested capital (ROIC) is -64.84%.
- Return on Equity (ROE)
- -1.73
- Return on Assets (ROA)
- -0.56
- Return on Invested Capital (ROIC)
- -64.84%
- Return on Capital Employed (ROCE)
- -0.66
- Revenue Per Employee
- 364.44K
- Profits Per Employee
- -767.29K
- Employee Count
- 1,664
- Asset Turnover
- 0.27
- Inventory Turnover
- 0.95
Valuation Ratios
The current PE Ratio of Insmed is -42.96. Insmed’s PEG ratio is -0.54.
- PE Ratio
- -42.96
- PS Ratio
- 17.49
- PB Ratio
- 36.50
- Price to FCF
- -40.42
- Price to Operating Cash Flow
- -44.51
- PEG Ratio
- -0.54
Income Statement
In the last 12 months, Insmed had revenue of 606.42M and earned -1.28B in profits. Earnings per share was -6.41.
- Revenue
- 606.42M
- Gross Profit
- 481.55M
- Operating Income
- -1.18B
- Pretax Income
- -1.27B
- Net Income
- -1.28B
- EBITDA
- -1.17B
- Earnings Per Share (EPS)
- -6.41
Cash Flow
In the last 12 months, operating cash flow was -595.62M and capital expenditures -61.95M, giving a free cash flow of -657.58M billion.
- Operating Cash Flow
- -595.62M
- Free Cash Flow
- -657.58M
- Free Cash Flow per Share
- -3.01
Dividends & Yields
Insmed pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.47%
- Earnings Yield
- -2.29%
Stock Price Statistics
- Beta
- 0.86
- 52-Week Price Change
- -4.48%
- 50-Day Moving Average
- 94.58
- 200-Day Moving Average
- 94.58
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- 41
Important Dates
Insmed upcoming earnings date is Feb 25, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 29, 2026
- Next Earnings Date
- Feb 25, 2027
- Ex-Dividend Date
- ―
Financial Position
Insmed as a current ratio of 3.83, with Debt / Equity ratio of 103.95%
- Current Ratio
- 3.83
- Quick Ratio
- 3.54
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- -0.22
- Interest Coverage Ratio
- -14.04
Taxes
In the past 12 months, Insmed has paid 5.03M in taxes.
- Income Tax
- 5.03M
- Effective Tax Rate
- -0.00
Enterprise Valuation
Insmed EV to EBITDA ratio is -54.50, with an EV/FCF ratio of -40.94.
- EV to Sales
- 17.71
- EV to EBITDA
- -54.50
- EV to Free Cash Flow
- -40.94
- EV to Operating Cash Flow
- -45.19
Balance Sheet
Insmed has CHF 1.15B in cash and marketable securities with CHF 741.17M in debt, giving a net cash position of CHF 405.46M billion.
- Cash & Marketable Securities
- CHF 1.15B
- Total Debt
- CHF 741.17M
- Net Cash
- CHF 405.46M
- Net Cash Per Share
- CHF 1.85
- Tangible Book Value Per Share
- CHF 2.06
Margins
Gross margin is 84.26%, with operating margin of -35.59%, and net profit margin of -39.85%.
- Gross Margin
- 84.26%
- Operating Margin
- -35.59%
- Pretax Margin
- -39.35%
- Net Profit Margin
- -39.85%
- EBITDA Margin
- -32.50%
- EBIT Margin
- -34.09%
Analyst Forecast
The average price target for Insmed is CHF 158.54, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- CHF 158.54
- Price Target Upside
- 72.95% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 17
- Revenue Growth Forecast
- 221.04%
- EPS Growth Forecast
- 57.11%
Scores
- Smart Score
- 6
- AI Score
- ―
